Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Analysts at Zacks Research reduced their Q1 2024 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Thursday, June 1st. Zacks Research analyst A. Chakroborty now anticipates that the biopharmaceutical company will earn ($1.58) per share for the quarter, down from […]